Recent studies have highlighted a key role of EVs in this pathogenesis mechanism, both in bone metastatic NSCLC, where increased plasma levels of AREG are correlated with poor prognosis [105], and in multiple myeloma [104], a highly osteoclastogenic disease where AREG is a known tumour growth factor [125]. Here, AREG is linked to plasma cell myeloma.